Modus Therapeutics Appoints Sedermera Fondkommission as Financial Advisor to Support Planned Listing on Nasdaq First North Growth Market
Modus Therapeutics utser Sedermera Fondkommission till finansiell rådgivare i avsikt att notera företaget på Nasdaq First North Growth Market
Modus Therapeutics Announces New Strategy for the Clinical Development of Sevuparin as a Potential Treatment for Sepsis/Septic shock
Modus Therapeutics tillkännager ny strategi för klinisk utveckling av Sevuparin som en potentiell behandling vid sepsis / septisk chock
Modus Therapeutics Announces the Results of its Global, Randomized, Placebo-Controlled Phase 2 Clinical Trial Evaluating Sevuparin for the Management of Acute Vaso-Occlusive Crisis (VOC) in Patients with Sickle Cell Disease (SCD)
